Valuation
- Market cap
- 159,557,000
- Revenue TTM
- $0
- Net income TTM
- $-57,440,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,909,300
- Avg volume
- 872,580
- Day's range
- $2.62 – $2.95
- Shares out
- 59,095,000
- Stochastic %K
- 6%
- Beta
- 1.47
- Analysts
- Strong Sell
- Price target
- $26.57
Company profile
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an invest...
Show more
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 646 844 0337
- Website
- https://www.protaratx.com
- Address
- 345 Park Avenue South, 3rd Floor, New York, United States
Latest news
No headlines yet.
